Trials / Terminated
TerminatedNCT00622479
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to: 1. To elucidate the mechanism involved in the sorafenib-induced hypophosphatemia and possible early effect of hypophosphatemia on bone mineral density 2. A secondary objective to assess the effect sorafenib treatment on evaluate left ventricular function (LVEF) and Beta-type natriuretic peptide in plasma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Sorafenib will be administered at 400mg BID for a 28 day cycle. |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-10-01
- Completion
- 2010-11-01
- First posted
- 2008-02-25
- Last updated
- 2014-12-18
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00622479. Inclusion in this directory is not an endorsement.